Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
View Patent ↗Provided herein are methods of detecting the presence of a pegylated enzyme, an enzyme-specific antibody (e.g., a neutralizing antibody or of a particular isotype), or a polyethylene glycol (PEG)-specific antibody in a sample, such as a bodily fluid or tissue of a patient. In certain embodiments, the enzyme is phenylalanine ammonia-lyase (PAL), such as Anabaena variabilis (Av) PAL administered to the patient as part of an enzyme substitution therapy for diseases or disorders, such as phenylketonuria (PKU), or cancer therapy.
1. A method for detecting the presence of pegylated Anabaena variabilis phenylalanine ammonia-lyase (AvPAL-PEG)-specific antibodies in a sample, said method comprising:
(a) contacting the sample with recombinant AvPAL-PEG enzyme, wherein the recombinant AvPAL-PEG enzyme is immobilized on a solid support via a PEG-specific antibody;
(b) optionally removing unbound sample;
(c) adding a phenylalanine substrate; and
(d) detecting the presence of enzymatic activity between the immobilized recombinant AvPAL-PEG enzyme and phenylalanine substrate;
wherein a reduction of enzymatic activity as compared to a reference sample having no neutralizing AvPAL-PEG-specific antibodies indicates the presence of neutralizing AvPAL-PEG-specific antibodies in the sample.
2. The method of claim 1 , wherein the enzymatic activity is conversion of the phenylalanine substrate to trans-cinnamic acid.
3. The method of claim 1 , further comprising measuring the amount of the neutralizing AvPAL-PEG-specific antibodies in the sample.
4. The method of claim 1 , wherein the AvPAL is an AvPAL variant.
5. The method of claim 4 , wherein the AvPAL variant is AvPAL_C503S, AvPAL_C565S or AvPAL_C565SC503S.
6. The method of claim 1 , wherein the sample comprises a bodily fluid or tissue.
7. The method of claim 6 , wherein the bodily fluid is blood, serum or plasma.
8. The method of claim 1 , wherein the sample is from a patient.
9. The method of claim 8 , wherein the patient is a mammal.
10. The method of claim 9 , wherein the mammal is a human.
11. The method of claim 8 , wherein the patient is a patient having elevated phenylalanine levels.
12. The method of claim 8 , wherein the patient has phenylketonuria.
13. The method of claim 8 , wherein the patient has cancer.
14. The method of claim 8 , wherein the patient has been, is, or will be administered a PAL, PAL variant, PAL-PEG, PAL-PEG variant or any combination thereof.